|
1
|
Prendiville S, Burman KD, Ringel MD, Shmookler BM, Deeb ZE, Wolfe K, Azumi N, Wartofsky L, Sessions RB. Tall cell variant: An aggressive form of papillary thyroid carcinoma. Otolaryngol Head Neck Surg 2016. [DOI: 10.1067/mhn.2000.100755] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Twenty-four cases of the tall cell variant (TCV), a subset of papillary thyroid carcinoma, were identified in a group of 624 patients with thyroid cancer. All pathology specimens were reviewed, and each patient's carcinoma was categorized according to characteristics on presentation, local recurrence, distant metastases, follow-up, and tumor-related mortality. The TCV group was compared with a historical control group (Mazzaferri and Jhiang: 1355 patients). The TCV group had a statistically higher percentage of stage 3 and 4 carcinoma, extrathyroidal invasion, and tumor size less than 1.5 cm than the control group. There was no statistical relationship between age greater than 50 years and stage in the TCV group. No relationship could be found between TCV histology and recurrence or mortality. These findings, combined with those of studies that link stage on presentation to poor outcomes, have led to our conclusion that TCV is an aggressive malignancy warranting appropriate treatment and close follow-up.
Collapse
Affiliation(s)
- Stephen Prendiville
- From the Departments of Otolaryngology–Head and Neck Surgery, Georgetown University Hospital, Washington, DC, and New York, New York
| | - Kenneth D. Burman
- the Departments of Medicine, Georgetown University Hospital, Washington, DC, and New York, New York
| | - Matthew D. Ringel
- the Departments of Medicine, Georgetown University Hospital, Washington, DC, and New York, New York
| | - Barry M. Shmookler
- Department of Pathology, Georgetown University Hospital, Washington, DC, and New York, New York
| | - Ziad E. Deeb
- and Department of Otolaryngology–Head and Neck Surgery, Georgetown University Hospital, Washington, DC, and New York, New York
| | - Katherine Wolfe
- and Department of Pathology, Georgetown University Hospital, Washington, DC, and New York, New York
| | | | - Leonard Wartofsky
- the Departments of Medicine, Georgetown University Hospital, Washington, DC, and New York, New York
| | - Roy B. Sessions
- and the Beth Israel Cancer Center, New York, Washington, DC, and New York, New York
| |
Collapse
|
|
2
|
Asare EA, Wang TS. Comparative effectiveness in thyroid cancer: key questions and how to answer them. Cancer Treat Res 2015; 164:67-87. [PMID: 25677019 DOI: 10.1007/978-3-319-12553-4_5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Controversies in treatment of thyroid cancer remain despite numerous published studies. Robust comparative effectiveness studies examining: (1) the role of prophylactic central compartment neck dissection (pCCND) in patients with papillary thyroid cancer (PTC); (2) the use of post-operative radioactive iodine (RAI) ablation therapy following total thyroidectomy; (3) use of low versus high doses of I-131 in RAI therapy; (4) thyroid hormone withdrawal (THW) versus recombinant thyroid stimulating hormone (rhTSH) prior to RAI; and (5) the role of routine measurement of serum calcitonin levels are needed to help strengthen existing treatment recommendations. Reasons for the controversies and suggestions for quality comparative effectiveness studies are discussed.
Collapse
Affiliation(s)
- Elliot A Asare
- Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA,
| | | |
Collapse
|
|
3
|
Affiliation(s)
- David T. Hughes
- Department of Surgery at the University of Michigan, Ann Arbor, Michigan
- Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY
| | - Gerard M. Doherty
- Department of Surgery at the University of Michigan, Ann Arbor, Michigan
| |
Collapse
|
|
4
|
Prendiville S, Burman KD, Ringel MD, Shmookler BM, Deeb ZE, Wolfe K, Azumi N, Wartofsky L, Sessions RB. Tall cell variant: an aggressive form of papillary thyroid carcinoma. Otolaryngol Head Neck Surg 2000; 122:352-7. [PMID: 10699809 DOI: 10.1016/s0194-5998(00)70047-7] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Twenty-four cases of the tall cell variant (TCV), a subset of papillary thyroid carcinoma, were identified in a group of 624 patients with thyroid cancer. All pathology specimens were reviewed, and each patient's carcinoma was categorized according to characteristics on presentation, local recurrence, distant metastases, follow-up, and tumor-related mortality. The TCV group was compared with a historical control group (Mazzaferri and Jhiang: 1355 patients). The TCV group had a statistically higher percentage of stage 3 and 4 carcinoma, extrathyroidal invasion, and tumor size less than 1.5 cm than the control group. There was no statistical relationship between age greater than 50 years and stage in the TCV group. No relationship could be found between TCV histology and recurrence or mortality. These findings, combined with those of studies that link stage on presentation to poor outcomes, have led to our conclusion that TCV is an aggressive malignancy warranting appropriate treatment and close follow-up.
Collapse
Affiliation(s)
- S Prendiville
- Departments of Otolaryngology-Head and Neck Surgery and Pathology, Georgetown University Hospital, Washington, DC 20007, USA
| | | | | | | | | | | | | | | | | |
Collapse
|